Kumarasamy N, Solomon Suniti, Chaguturu Sreekanth K, Cecelia Anitha J, Vallabhaneni Snigdha, Flanigan Timothy P, Mayer Kenneth H
YRG Centre for AIDS Research and Education, Voluntary Health Services, Chennai, India.
Clin Infect Dis. 2005 Nov 15;41(10):1525-8. doi: 10.1086/497267. Epub 2005 Oct 13.
The number of individuals seeking treatment for infection with human immunodeficiency virus increased as the cost of highly active antiretroviral therapy (HAART) decreased 20-fold after the introduction of generic HAART in India in the year 2000. The incidence of tuberculosis and opportunistic infections decreased to <2 cases per 100 person-years. Death rates decreased from 25 to 5 deaths per 100 person-years between 1997 and 2003.
2000年印度引入高效抗逆转录病毒疗法(HAART)的仿制药后,高效抗逆转录病毒疗法的成本下降了20倍,寻求治疗人类免疫缺陷病毒感染的人数有所增加。结核病和机会性感染的发病率降至每100人年<2例。1997年至2003年期间,死亡率从每100人年25例降至5例。